The striking benefits achieved with emerging treatment options for recalcitrant connective tissue diseases offer the ...
Researchers will evaluate the IL1RAP-targeted nadunolimab with a checkpoint inhibitor in up to 24 metastatic microsatellite stable colorectal cancer patients.
The FDA granted fast track designation (FTD) to IBI3003, a first-in-class trispecific antibody, for the treatment of patients ...
Dealbreaker on MSN
Startup Fortitude Bio launches to beat drug resistance in cancer, expand ADCs to autoimmune disease
The company joins a group of degrader ADC (or DAC) developers that includes Bristol Myers Squibb and Pfizer.
On January 12, 2026, AbbVie and RemeGen announced an exclusive licensing agreement granting AbbVie rights to develop, ...
Advanced gastroesophageal adenocarcinoma (GEA) with HER2 positivity has long presented significant treatment challenges, with first-line therapies offering limited survival benefits despite advances ...
Allergic diseases represent a major global health burden, placing significant strain on healthcare systems worldwide. Severe ...
PRESS RELEASEStarkAge Therapeutics Announces Research Collaboration with Gustave Roussy to Advance Senolytic Therapies in Digestive CancersThe ...
The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene ...
What do you get when you insert a molecular glue degrader into an antibody-drug conjugate (ADC)? Fortitude Biomedicines is in ...
COLORADO SPRINGS, CO, UNITED STATES, January 14, 2026 /EINPresswire.com/ -- Lahjavida Bio, a biotechnology company ...
A new study reveals a critical vulnerability in a brain receptor targeted by a rare autoimmune disease. Researchers have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results